Evidence map›Paper›PMID 32576210›Full record

ArticleJournal of orthopaedic surgery and research2020

Clinical effect of intramuscular calcitonin compared with oral celecoxib in the treatment of knee bone marrow lesions: a retrospective study.

Jiaming Zhou, Wuyi Xiong, Pengguo Gou, Zhao Chen, Xing Guo, Xiaoyang Huo, Yuan Xue

Open access · goldAbstract readComparative Study
In one paragraph

Article in Journal of orthopaedic surgery and research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Effects of calcitonin on lumbar spinal stenosis.Archives of orthopaedic and trauma surgery · 2024
    Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jiaming ZhouDepartment of Orthopaedic Surgery, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Wuyi XiongDepartment of Orthopaedic Surgery, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Pengguo GouDepartment of Orthopaedic Surgery, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Zhao ChenDepartment of Orthopaedic Surgery, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Xing GuoDepartment of Orthopaedic Surgery, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Xiaoyang HuoDepartment of Orthopaedic Surgery, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Yuan XueDepartment of Orthopaedic Surgery, Tianjin Medical University General Hospital, Tianjin, 300052, China. xueyuanzyy@163.com.
Tianjin Medical University General Hospital · CN

Funding

National Natural Science Foundation of China 81871124
6 · The paper itself

Abstract

backgroundBone marrow lesions (BMLs) are a common finding in patients with osteoarthritis (OA), which are predictors of progression and pain related to cartilage damage in OA. The objective of the present research was to compare the short-term clinical effect of intramuscular calcitonin and oral celecoxib in treating knee BMLs. PATIENTS AND

methodsBetween January 2016 and December 2018, the medical records of patients with knee BMLs treated by intramuscular calcitonin or oral celecoxib were reviewed. Visual analog scale (VAS) and the Western Ontario and McMaster University Osteoarthritis Index (WOMAC) were used to assess knee pain and function, respectively. BMLs were assessed by MRI scans and were scored by the modified Whole-Organ MRI Score (WORMS). The safety of these two medications was also evaluated.

resultsA total of 123 eligible patients who received calcitonin treatment (n = 66) or celecoxib treatment (n = 57) were included. All patients were followed up clinically and radiographically for 3 months. The VAS and WOMAC scores were lower statistically in calcitonin group than celecoxib group at 4-week and 3-month follow-up. For BMLs, the WORMS scores in the calcitonin group were significantly lower than the celecoxib group. Besides, statistically higher MRI improvement rates were found in the calcitonin group compared with the celecoxib group at 4-week follow-up (21.21% vs. 7.01%; P = 0.039) and 3-month follow-up (37.88% vs. 15.79%; P = 0.006).

conclusionIntramuscular calcitonin 50 IU once daily demonstrated a better short-term effect for knee BML patients compared with oral celecoxib 200 mg twice per day.

Indexed as

Administration, OralAgedAnti-Inflammatory Agents, Non-SteroidalBone Density Conservation AgentsBone DiseasesBone Marrow DiseasesCalcitoninCelecoxibFemaleHumansInjections, IntramuscularMaleMiddle AgedOsteoarthritis, KneePain MeasurementRetrospective StudiesAnti-Inflammatory Agents, Non-SteroidalBone Density Conservation AgentsCalcitoninCelecoxibBone marrow lesionsCalcitoninCelecoxibOsteoarthritis

Identifiers

PMID32576210
PMCPMC7310554
OpenAlexW3035801628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.